Market Research Report
Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe
|Published by||BCC Research||Product code||256188|
|Published||Content info||140 Pages
|Global Markets for Diabetes Therapeutics and Diagnostics -- Focus on Europe|
|Published: January 1, 2013||Content info: 140 Pages||
An overview of the global market for prescription generic drugs used in the treatment of diabetes and devices and instruments used for diagnosis and monitoring of diabetes, with a focus on Europe
Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
Identification of markets based on epidemiological data and projections, plus information on R&D trends and differential market potential on a country-by-country basis
Discussion of healthcare policies, demographics, and the wider economic environment
Examination of therapeutic categories, such as insulins and oral hypoglycemic agents, and devices including blood glucose monitors and accessories
Comprehensive company profiles of major players.
The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for drugs used in the treatment of diabetes and for devices and instruments used in the diagnosis and monitoring of diabetes. Special emphasis is given to major forces contributing to the vigorous growth of the diabetes market. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2017. These forecasts are based on epidemiological data and projections, as well as on information about R&D trends and differential market potential on a country-by-country basis. Health care policies, demographics, and the wider economic environment are also taken into account.
It is widely recognized that the prevalence of the most common type of diabetes mellitus, Type 2, is now reaching epidemic proportions all over the world. Cases of Type 1 diabetes are also on the rise, although to a less spectacular degree. These trends are of great concern, not only to the individuals affected, but also to governments and providers of health care. Indeed, the economic consequences of diabetes are vast, involving not only the direct burden of managing the disease but also the common and often catastrophic complications such as cardiovascular disease, peripheral neuropathy, and blindness.
Prompt diagnosis and effective treatment of diabetes are essential, not optional, priorities for governments and health care agencies. The already large market for diabetes monitoring and treatment will certainly grow in line with increasing incidence and with improvements in diagnosis. Thus diabetes is of great commercial significance to the suppliers of drugs used in treatment and to the suppliers of devices needed for disease monitoring.
Among the information needs of companies in this field is an accurate and up-to-date assessment of the current extent of the diabetes epidemic, its likely evolution over the next five years, and the impact of drugs and technical developments now in the pipeline.
This report discusses the implications of the above-mentioned trends in the context of the current size and growth of the diabetes market, discussed both in global terms and in terms of the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on merger and acquisition (M&A) activity. Five-year global sales forecasts are provided for main drug and device categories, and breakdowns are provided for several national markets.
A comprehensive refresher course on diabetes is provided as an appendix.
The dimensions of the surging diabetes epidemic can be witnessed in stark outline against previous smaller estimates only a few years back. Increased awareness of this "modern plague" has led naturally to improved and more frequent testing practices. This new awareness has also led to improved treatment compliance by patients. Added to these are the more expensive therapies and increased penetration of continuous glucose monitoring (CGM) approaches, which all combine to build a public health menace of accelerating proportions.
For the purpose of market analyses in this report, the global market is defined as 13 countries which together make up over 80% of the total diabetes universe. These countries are the U.S., Canada, Brazil, Mexico, China, India, Japan, Russia, Germany, France, Italy, Spain and the U.K.
Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories discussed include insulins and oral hypoglycemic agents, devices including blood glucose monitors and accessories, and software aids to self-management of diabetes by patients.
Primary research for this report included interviews with leading individuals in relevant companies and medical associations; primary sources of published data include epidemiological and economic studies, company annual reports, SEC filings, and government publications. Secondary sources consisted of literature searches, industry journals, and other commercial publications. Data for market estimates and forecasts were pooled from a range of sources, critically assessed by BCC.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the diabetes marketplace, including company senior management executives seeking to base their strategic decisions on the best available information with regard to market forces and trends. However, it is also aimed at managers and executives in marketing, research, planning, and sales departments who need readable, comprehensive, and up-to-date background information on the marketplace in which they are operating.
Sources of information included marketing strategists, industry executives, government and professional agencies, and surveys of physicians. Company annual reports and SEC filings, journal articles, and data from health care institutions were also mined, as well as publications of relevant associations such as the International Diabetes Federation and the American and British Diabetic Associations.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the diabetes marketplace covering both therapeutic and monitoring aspects.